Jones Trading cuts TFF Pharmaceuticals target to $13

On Thursday, Jones Trading adjusted its price target for TFF Pharmaceuticals (NASDAQ:TFFP), a company specializing in drug delivery systems, reducing it to $13.00 from the previous $25.00, while retaining a Buy rating for the stock. The modification follows TFF Pharmaceuticals' recent activities, including a public conference call and webcast held on March 27, where the company provided updates on its TFF TAC and TFF VORI programs.

The company also released its fourth-quarter financial results for 2023, which highlighted positive developments for both TFF TAC, aimed at preventing acute rejection in lung transplants, and TFF VORI. TFF Pharmaceuticals is channeling its resources towards advancing the TFF TAC program and is seeking strategic alternatives to progress TFF VORI, which may include partnerships, collaborations, or government funding.

Despite the promising results, the company's financial situation presents a challenge. With approximately $5.5 million at the end of the fourth quarter of 2023 and an additional $1.2 million from a recent direct offering, there is concern about the company's ability to fund operations further into 2024. The analyst from Jones Trading believes that the current market price does not fully reflect the potential of TFF TAC, TFF VORI, or the company's underlying technology platform.

The decision to lower the price target to $13 is attributed to the removal of potential revenues from TFF VORI from the analyst's financial model. This revision reflects the need for TFF Pharmaceuticals to secure non-dilutive funding and the uncertainty surrounding the advancement of TFF VORI. The analyst expressed confidence in the long-term potential of TFF Pharmaceuticals' programs despite the immediate financial risks.

For investors following TFF Pharmaceuticals (NASDAQ:TFFP), the latest metrics from InvestingPro paint a detailed picture of the company's current financial health and market performance. The company holds a modest market capitalization of $13.13 million, indicating its relatively small size in the pharmaceutical industry. Despite its innovative drug delivery systems, TFFP's financial data reflects some challenges, with a significant operating income loss of approximately $21.89 million for the last twelve months as of Q4 2023. This loss is mirrored in its operating income margin, which stands at a stark -2564.21%.

Moreover, TFFP's stock has experienced a notable decline, with a one-month price total return of -44.38% and a one-year price total return of -69.42%, suggesting that investors have been bearish on the stock's performance. This aligns with the InvestingPro Tips, which highlight the company's rapid cash burn and the stock's poor performance over the last week and month. Additionally, the company's valuation implies a poor free cash flow yield, which could be a concern for potential investors looking for value.

Get The App

Join the millions of people who stay on top of global financial markets with Investing.com.

Download Now

However, it's not all negative for TFFP. The company's liquid assets do exceed its short-term obligations, providing some financial flexibility in the near term. This could be crucial as the company navigates its funding strategy and seeks to advance its TFF TAC and TFF VORI programs. For investors seeking a more comprehensive analysis, there are additional InvestingPro Tips available, offering deeper insights into TFF Pharmaceuticals' financials and market prospects. By using the coupon code PRONEWS24, readers can get an additional 10% off a yearly or biyearly Pro and Pro+ subscription to gain access to these valuable tips.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.